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SUMMARY
Several abnormalities in the insulin-like growth factor-1 (IGF1) and erbB receptors
pathways stimulate the growth and survival of lung cancer cells but their mechanisms of
action and cooperation are poorly understood. In this report, we have identified a new
mechanism of apoptosis inhibition by amphiregulin through an IGF1-dependent survival
pathway in Non-Small Cell Lung Cancer (NSCLC) cells: amphiregulin activates the IGF1
receptor that in turn induces the secretion of amphiregulin and IGF1.
In the absence of serum, the NSCLC cell line H358 resists apoptosis and secretes factors
protecting the NSCLC cell line H322 from serum deprivation apoptosis. IGF1 receptor
inhibitor AG1024 as well as epidermal growth factor receptor inhibitors AG556 and ZD1839
restore apoptosis in H322 cells cultured in H358 conditioned medium. Accordingly, the anti-
apoptotic activity of H358 conditioned medium is completely abolished after incubation with
anti-amphiregulin neutralizing antibody and only partially with anti-IGF1 neutralizing
antibody. H358 conditioned medium and amphiregulin induce the IGF1 receptor
phosphorylation in H322 cells, which is prevented by anti-amphiregulin neutralizing
antibody. H358 cells secrete a high level of amphiregulin that, in combination with IGF1,
prevents serum deprivation apoptosis. Finally, IGF1 receptor inhibitor blocks amphiregulin
and IGF1 release by H358 cells.
Hurbin A. et al., Amphiregulin activates an IGF1-R dependent survival pathway
3
INTRODUCTION
In lung cancer, well characterized molecular abnormalities affect cell cycle control and
apoptosis (1); in addition, a variety of peptide hormones and growth factors induce autocrine
or paracrine stimulation of cell survival, proliferation, migration and angiogenesis. While
tumor growth of small cell lung cancer is mainly mediated by neuropeptides such as
bombesin-related peptides that bind to G protein-coupled receptor, the major
autocrine/paracrine loops for non-small cell lung cancer (NSCLC)1 cells involve growth
factors that bind to tyrosine kinase receptors (2).
The erbB receptor family contains four distinct members: the epidermal growth factor
receptor (EGFR, erbB-1/HER1), erbB-2/neu (HER2), erbB-3 (HER3) and erbB-4 (HER4).
These receptors consist of an extracellular domain containing the ligand binding domain, a
hydrophobic transmembrane domain and an intracellular domain conferring tyrosine kinase
activity (3). Binding of specific ligands induces homo- or heterodimerization of the receptors
within members of the erbB family (4) and activates distinct intracellular signal transduction
pathways and biological responses, including cellular proliferation, differentiation, migration
and survival. Five ligands of EGFR, the epidermal growth factor (EGF), transforming growth
factor α (TGFα), amphiregulin (AR), heparin-binding EGF (HB-EGF) and betacellulin, can
be produced by tumorigenic and, to a lesser extent, by non-tumorigenic human lung epithelial
cells (5-7). As most cells of epithelial origin, NSCLC cells overexpress members of the erbB
receptor family, in particular the EGFR and erbB-2/neu, but the prognostic impact of this
overexpression is still controversial (5,6). Overexpression of TGFα and AR has been
associated with shortened survival of patients with NSCLC (5,6,8,9).
Type 1 insulin like-growth factor receptor (IGF1-R) is also overexpressed in human lung
tumors (10,11). The IGF1-R is composed of two extracellular α subunits with the ligand-
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binding domain and two β  subunits that contain a single transmembrane domain and an
intracellular domain with the tyrosine kinase activity. IGF1-R binds insulin-like growth
factor-1 (IGF1) with high affinity and insulin-like growth factor-2 (IGF2) with much lower
affinity. High levels of circulating IGF1 detected in patients with lung cancers (12,13)
suggested that the IGF1/IGF1-R pathway could be involved in the pathogenesis of this
disease. IGF1 is a potent stimulator of mitogenesis (14,15) and can promote cellular
differentiation and transformation (16-18). Furthermore, IGF1 is a major survival factor and
protects cells from apoptosis under a wide variety of circumstances (19,20), including
cytotoxic agents (21-25), overexpression of myc (26), caspase activation (27), irradiation with
UV-B (28), brain ischemia (29) and serum withdrawal (27,30-33).
Cross talk between the IGF1-R, the EGFR and their ligands has been reported.
Stimulation of IGF1-R signaling interferes with the antitumoral activity of EGFR inhibitor
(34) or of Trastuzumab, a monoclonal antibody used in clinic to inhibit the growth of erbB-
2/neu expressing tumors (35). In addition, prolonged activation of the intracellular kinase
ERK2 by EGF in mouse embryo fibroblasts requires a functional IGF1-R (36). Moreover,
stimulation of the IGF1-R intracellular pathway was abolished by the blockade of EGFR in
several cell systems (37-39). In keratinocytes, IGF1 induces the production and secretion of
TGFα and AR (37) and in COS-7 cells, stimulation of the IGF1-R transactivates the EGFR,
via a mechanism involving matrix metalloprotease-dependent release of HB-EGF (39). Thus
IGF1/IGF1-R pathway transactivate the EGFR via an autocrine release of EGF-like factors
(37,39).
Although the role of IGF1-R and EGFR pathways in growth and survival of lung cancer
cells is well understood, their mechanism of action and cooperation are poorly understood. In
this report, we analyzed the inhibition of serum deprivation apoptosis in two NSCLC cell
lines H358 and H322 and showed that a reciprocal activation of AR and IGF1 pathways
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induced cell survival. Indeed, we show here that AR phosphorylates the IGF1-R and that the
subsequent activation of IGF1-R pathway induces the secretion of AR and IGF1. Subsequent
cross talk between those growth factors and receptors activates a survival pathway in NSCLC
cell lines.
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EXPERIMENTAL PROCEDURES
Cell culture, serum withdrawal and H358 conditioned medium
The human H358, H322, A549, HEL, K562 and Jurkat cell lines were cultured in RPMI
1640 medium; H69, H1417 and H2170 cells in RPMI medium supplemented with glucose 2.5
µg/l, HEPES 10 mM, Na pyruvate 1 mM; CALU-1 and SAOS cells in McCoy’s medium;
MCF7 and HELA cells in DMEM medium; H810, H720 and H2106 cells in Hites medium;
NHBE cells in SAGM medium. Media were supplemented with 10 or 5 % heat-inactivated
fetal calf serum (FCS) and cells were cultured at 37 °C in a humidified atmosphere of 5 %
CO2. All products were purchased from Gibco (Cergy Pontoise, France).
For serum deprivation, cells were rinsed once in PBS and cultured for at least 8 h in
serum-free medium, which was then changed and culture continued in serum-free medium or
in serum-free conditioned medium for the desired time. Conditioned media (CM) from cells
were collected 72 h after serum-free culture, centrifuged (5000g) at 4 °C and stored at -80 °C
until use.
Drug treatment and immunoneutralization
Tyrphotins AG556, AG1024 or AG1295 (Alexis Biochemical, Laufelfingen,
Switzerland), quinazolin ZD1839 (Iressa, kindly provided by Dr R. Defrance, Astra-Zeneca,
Rueil-Malmaison, France), CRM197 (Sigma-Aldrich, Saint Quentin Fallavier, France) were
dissolved in DMSO; tyrphotin AG825 (Alexis Biochemical) in DMSO/methanol (v/v); 1,10-
phenanthroline (Sigma-Aldrich) in ethanol and keep at -20 °C until use. AR and IGF1
recombinant proteins (Sigma-Aldrich) were dissolved in fresh medium just before use.
Anti-human EGF or AR mouse monoclonal, anti-human TGFα, betacellulin or IGF2 goat
polyclonal (R&D Systems Europe, Ltd., Abingdon, UK) or anti-human IGF1 goat polyclonal
(Oncogene Research Products, Fontenay sous Bois, France) neutralizing antibodies were
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incubated overnight at 4 °C in H358 CM. The immunoneutralized H358 CM was then added
to H322 cells for 96 h.
Quantification of apoptotic cell death
The morphological changes related to apoptosis were assessed by fluorescence
microscopy after Hoechst 33342 (5 g/ml) staining of cells (Sigma- Aldrich) and the percent of
apoptotic cells was scored after counting at least 200 cells.
The proteolytic activation of pro-caspase-3 was evaluated by Western Blotting: cells were
washed twice in PBS and incubated in lysis buffer (Tris-Hcl 50 mM pH 7.4, Nacl 150 mM,
EDTA 1 mM, Nonidet P-40 0.5 %, NaF 1 mM, Na3VO4 1 mM, phenylmethylsulfonyl
fluoride (PMSF) 0.5 mM, leupeptin 10 µg/ml, aprotinin 10 µg/ml and pepstatin 10 µg/ml) for
30 min on ice. Protein content was assessed by the Bio-Rad DC Protein Assay kit (Bio-Rad
Lab., Ivry sur Seine, France). Cell lysates (40 µg of protein) were subjected to polyacrylamide
gel electrophoresis and transferred onto polyvinylidene difluoride membrane (PVDF,
Millipore, Saint Quentin les Yvelines, France). After blocking nonspecific binding sites with
5 % nonfat milk in TPBS (PBS, Tween 20 0.1 %) for 30 min at room temperature, the
membrane was incubated overnight at 4 °C with primary anti-human caspase-3 rabbit
polyclonal antibody 1:1000 (Pharmingen, Becton Dickinson, Le Pont de Claix, France),
diluted in TPBS. To ensure equal loading and transfer, membranes were also probed for actin
using anti-actin rabbit polyclonal antibody 1:3000 (Sigma-Aldrich). The immunoreactive
proteins were visualized using horseradish peroxidase conjugated goat anti-mouse antibody
diluted 1:10000 in TPBS and enhanced chemiluminescence (ECL) (Amersham Pharmacia
Biotech, Orsay, France).
In some experiments, active caspase-3 was detected by flow cytometry using
phycoerythrin (PE) -conjugated monoclonal active caspase-3 antibody kit (Becton Dickinson
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PharMingen) following the manufacturer’s instructions. Analysis was performed on a Becton
Dickinson FACScan flow cytometer. Red fluorescence (PE, FL-2) was detected at 575 nm.
Cellular DNA was extracted by a salting-out procedure and detected after agarose gel
electrophoresis.
IGF1-R immunoprecipitation
Cells were washed twice in PBS and incubated in lysis buffer (Tris-HCl 50 mM pH 7.4,
NaCl 150 mM, EDTA 1 mM, Nonidet P-40 0.5 %, NaF 1 mM, Na3VO4 1 mM, PMSF 0.5
mM, leupeptin 10 µg/ml, aprotinin 10 µg/ml and pepstatin 10 µg/ml for H322 cells; Tris-Hcl
50 mM pH 7.4, Nacl 150 mM, Nonidet P-40 1 %, deoxycholate sodium 0.5 %, SDS 0.1 %
NaF 1 mM, Na3VO4 1 mM, PMSF 0.5 mM, leupeptin 10 µg/ml, aprotinin 10 µg/ml and
pepstatin 10 µg/ml for H358 cells) for 30 min on ice. Immunoprecipitation of IGF1-R was
performed using 1 µg anti-IGF1-R β  subunit rabbit polyclonal antibody (Santa Cruz
Biotechnology, Tebu, Le Perray en Yvelines, France), overnight at 4 °C with continuous
agitation. Immune complexes were collected using 80 µl of protein G-agarose (Sigma
Aldrisch) following continuous agitation for 1 h at 4 °C. Immunoprecipitates were resolved
by SDS-PAGE and transferred to PVDF membranes for protein immunoblotting. Nonspecific
binding sites were blocked with 3 % BSA in TTBS (TBS, Tween 20 0.1 %) for 30 min at
room temperature. Protein tyrosine phosphorylation was detected by 1:1000 dilution of anti-
phosphotyrosine mouse monoclonal antibody (Upstate Biotechnology, Euromedex,
Mundosheim, France). IGF1-R was detected by 1:1000 dilution of the anti-IGF1-R β subunit
rabbit polyclonal antibody. The immunoreactive proteins were visualized using horseradish
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peroxidase-conjugated goat anti-mouse 1:20000 or anti-rabbit 1:10000 antibodies in TTBS
and ECL (Amersham Pharmacia Biotech.).
AR and IGF1 dosage
Conditioned media were obtained as previously described from serum-deprived H358 or
H322 cells. Cells were plated at a density of 5 X 106 cells/flask (75 cm2) or 8 X 105 cells/well
(6 wells plate). AR in the medium was analyzed using specific ELISA. Primary monoclonal
anti-human AR antibody (2 µg/ml, R&D Systems) was coated to the bottom of 96-well plates
and incubated overnight at room temperature. The wells were washed with TPBS (PBS,
Tween 20 0.05 %), blocked by the addition of PBS containing 1 % BSA and 5 % sucrose for
1 h at room temperature and washed again. Solutions containing varying concentrations of
biologically active recombinant amphiregulin or assay samples were diluted in buffer (Tris 20
mM pH 7.3, NaCl 150 mM, BSA 0.1 %, Tween 20 0.05 %) and incubated 2 h at room
temperature. The wells were washed prior to incubation with a mixture of the secondary
biotinylated anti-human amphiregulin antibody (25 ng/ml, R&D Systems) and horseradish
peroxidase-conjugated avidin 1:250 in buffer. Following incubation for 2 h at room
temperature, the wells were incubated with substrate reagents A (cat. 2606KC) and B (cat.
2607KC) (1:1 ratio, Becton, Dickinson, PharMingen) 30 min in the dark. Adding H2SO4 1M
stopped the reaction and optical density was measured at 450 nm with an ELISA plate reader.
IGF1 level in culture medium was analyzed by radioimmunoassay using the IGF1 extraction
kit (Nichols Institute Diagnostics) following the manufacturer’s instructions.
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RESULTS
H358 NSCLC cells are resistant to serum deprivation apoptosis and secrete anti-
apoptotic factors
After 96 h of culture in serum-free medium, H322 cells underwent apoptosis as revealed
by morphological change (figure 1A). These changes coincided with DNA fragmentation
visualized after agarose gel electrophoresis (figure 1B) and proteolytic cleavage of pro-
caspase-3 in its p12 active fragment (figure 1C). Conversely, no evidence of cell death was
detected in H358 cells, even after 120 hours of serum deprivation (figure 1A-C).
In order to determine whether the resistance of H358 cells was due to the constitutive
activation of a survival pathway or whether those cells secrete anti-apoptotic factors, serum-
free conditioned medium from H358 cells (H358 CM) was collected and used for culturing
H322 cells. H358 CM inhibited apoptosis of H322 cells, evaluated by the absence of
morphological changes or cleavage of caspase-3, after 96 h of culture (figure 1D). This effect
was dose-dependent (data not shown).
Inhibition of serum deprivation apoptosis in H322 and H358 NSCLC cell lines by EGF
and IGF1 receptors
Human lung cancer cells are known to express EGFR, erbB-2/neu, IGF1-R and platelet-
derived growth factor (PDGFR) receptors. We first considered the possible involvement of
these receptors in the survival of H322 cells cultured in H358 CM. Serum-deprived H322
cells were incubated in medium supplemented with 10 % serum, in serum-free medium or in
H358 CM in the presence of several highly specific inhibitors (figure 2). Tyrphostin AG825
and AG1295, which inhibited respectively the erbB-2/neu and the PDGFR, did not modify the
survival of H322 cells cultured in presence of serum, in serum-free medium or in H358 CM
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(figure 2A, B). The IGF1-R inhibitor tyrphostin AG1024 (1 µM) did not modify apoptosis in
H322 cells cultured in the presence or in the absence of serum, but restored, in a dose
dependent manner, apoptosis when cells are cultured in H358 CM (figure 2C). Both EGFR
inhibitors tyrphostin AG556 (20 µM) and quinazolin ZD1839 (500 nM) did not modify
apoptosis of the cells in the presence of serum, increased the level of apoptosis of the cells
when cultured in serum-free medium and restored apoptosis in H322 cells cultured in H358
CM (figure 2D, E).
We then analyzed the survival of H358 cells cultured in serum-free medium in presence
or absence of the same inhibitors (Table 1). In presence of serum none of the inhibitors
induced apoptosis of H358 cells. In contrast, the EGFR inhibitor tyrphostin AG556 (10 µM)
as well as the IGF1-R inhibitor tyrphostin AG1024 (10 µM) restored H358 cells apoptosis
when cultured in serum-free medium (Table 1). Conversely, concentration of up to 20 or 40
µM of the erbB-2/Neu inhibitor tyrphostin AG825 and the PDGFR inhibitor tyrphostin
AG1295 had no effect on H358 cell survival (Table 1). These results were confirmed by a
western analysis of proteolytic activation of pro-caspase-3 in its p12 active fragment (figure
3).
Altogether, these data highly suggested that H358 cells secreted autocrine/paracrine
factors activating the IGF1-R and EGFR in H358 and H322 cells.
AR and IGF1 inhibit serum deprivation apoptosis of H358 and H322 cells
In order to identify factors of the EGF and IGF families involved in the anti-apoptotic
activity of H358 CM, we used neutralizing antibodies. The anti-apoptotic activity of H358
CM was completely abolished by a pre-incubation with the anti-AR neutralizing antibody and
to a lower extent (about 50 %) by the anti-IGF1 antibody (Table 2). In contrast, pre-
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incubation of H358 CM with anti-EGF, anti-TGFα, anti-betacellulin, anti-IGF2 antibodies, or
with CRM197, which neutralized the HB-EGF, did not alter anti-apoptotic activity of H358
CM (Table 2). These results were confirmed by treatment of H358 cells with an antisense
oligonucleotide directed against the AR mRNA, which significantly restored apoptosis of
H322 cells cultured in H358 CM (not shown).
We then quantified AR and IGF1 secreted by H358 cells cultured in the absence of serum
(Table 3). The level of IGF1 secreted by H358 cells was not significantly different than those
secreted by other cancer cell lines from lung or other origins, but the level of AR was very
high. Furthermore, H322 cells secreted IGF1 but AR was below detectable levels (Table 3).
We then used AR or IGF1 recombinant proteins to analyze inhibition of H322 cells
serum deprivation apoptosis. When AR or IGF1 were used as single agent, the apoptosis
inhibition was dose-dependant and observed only at high concentrations (figure 4). In
contrast, when AR and IGF1 proteins were used in combination, the maximal apoptosis
inhibition observed in H322 cells cultured in serum-free medium was reached with 5 ng/ml of
AR and 1 ng/ml of IGF1, the concentrations present in H358 CM (figure 4).
These data confirmed that both AR and IGF1 are involved in the anti-apoptotic activity of
H358 CM and suggested a cooperation between the growth factors to inhibit serum
deprivation apoptosis in the two cell lines.
Secretions of AR and IGF1 are induced by the IGF1-R
The release of soluble EGF-like growth factors involves proteolysis mediated by matrix
metalloproteases (40,41) and the IGF1-R (37,39). In order to determine the mechanism by
which a large quantity of AR is released by H358 cells, we assessed whether treatment with
the IGF1-R inhibitor AG1024 or the metalloproteases inhibitor 1,10-phenanthroline affected
the AR release by serum-deprived H358 cells. As shown in figure 5, incubation with AG1024
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or 1,10-phenanthroline both markedly decreased AR level detected in the serum-free culture
medium. In contrast, incubation of H358 cells with 1,10-phenanthroline had no effect on
IGF1 level, but AG1024 decreased IGF1 release in the serum-free culture medium (figure 5).
The data suggested that the IGF1-R pathway regulated the AR secretion through
metalloproteases activation. Furthermore, the IGF1-R was also involved in IGF1 release.
AR activates the IGFI-R in H322 cells
We then analyzed the activation of the IGF1-R in H322 cells. The IGF1-R was
unphosphorylated in H322 cells cultured in serum-free medium (figure 6A, B). As expected,
IGF1 induced the tyrosine phosphorylation of its receptor. Moreover, we observed the
phosphorylation of the IGF1-R on H322 cells after 30 min of incubation in H358 CM (figure
6A). This phosphorylation was prevented when H358 CM was pre-incubated with the anti-
AR neutralizing antibody (figure 6B). Moreover, incubation of H322 cells for 30 min with
AR recombinant protein in serum-free medium induced the phosphorylation of the IGF1-R
(figure 6B). Thus, in H322 cells, AR activated the IGF1-R. Accordingly, H358 cells cultured
in serum-free medium, which secreted IGF1 and high amount of AR, presented a constitutive
phosphorylation of the IGF1-R (figure 6C).
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DISCUSSION
We have shown here that the reciprocal activation of AR and IGF1 pathways induced
inhibition of serum deprivation apoptosis in NSCLC cell lines H358 and H322. We
demonstrated, for the first time to our knowledge, that AR activated the IGF1-R, which in
turn induced the secretion of AR and IGF1. Thus, AR can inhibit apoptosis in NSCLC cells
through an IGF1-R dependent pathway.
AR, an EGF-related growth factor produced by epithelial cells, functions as an
autocrine/paracrine cell proliferation factor (42,43). Several lines of evidence suggest that AR
is an autocrine growth factor in human carcinoma cells (44-51) and tumorigenicity of a
human breast epithelial cell line is abolished by treatment with AR antisense (49). A
protective role of the EGF-like growth factors against apoptosis has been demonstrated in
several non-transformed and tumor cell types (52-56). Accordingly, anti-apoptotic activity of
AR has been suggested by a study in human breast carcinoma cells (48). AR is overexpressed
in a significant percentage of tumorigenic human lung epithelial cells (7). Moreover, an
extensive analysis of the expression of EGF-related peptides and receptors in a large group of
195 stage I-IIIA NSCLC patients showed that enhanced AR expression was the only variable
to be significantly correlated with a reduced overall survival (6). We confirm here that AR
could be a potent inducer of NSCLC cells autonomous survival.
IGF1 and its receptor the IGF1-R contribute to carcinogenesis. The IGF1-R effects
several growth-promoting functions: it stimulates mitogenesis (14,15), promotes cellular
transformation (16,18) and protects cells from apoptosis (19-33); a dominant-negative
IGF1-R mutant induced extensive apoptosis in vivo and inhibited growth in vitro of rat
glioblastoma C6 cells (57). We confirmed in this study that the activation of the IGF1/IGF1-R
pathway inhibits NSCLC cell apoptosis.
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Known EGFR ligands, including AR, are synthesized as cell surface precursor proteins
and soluble growth factors are produced by proteolysis (40,41). Activation of the IGF1-R
pathway induce the secretion of soluble EGF-related peptide such as AR and TGFα in
keratinocytes and HB-EGF in COS-7 cells that in turn activate the EGFR (37,39,58). We
showed here that inhibition of the IGF1-R or the metalloproteases on H358 cell line decreased
the level of secreted AR, suggesting that the IGF1-R increased the shedding of pro-AR from
H358 cell surface by metalloprotease activation, as described for HB-EGF (39). Whether or
not this mechanism is sufficient to explain the very high level of AR secreted by H358 cells is
under investigation. Our results showed also here that AR stimulated the IGF1-R which in
turn induced the release of AR, an amplification phenomenon which could also explain the
high levels of AR secreted by H358 cells. Furthermore, H358 cells express a mutated
constitutively active Ras protein (59) and Ras activation has been shown to increase the
production of EGF-related peptides (60,61). Accordingly, H322 cells, which did not secrete
AR, express a wild-type Ras protein (59).
AR is known to elicit its biological activity through binding and activation of the EGFR.
We demonstrated that AR can also induce the phosphorylation of IGF1-R. Furthermore, in
H322 cells, the anti-apoptotic activity of H358 CM was strongly inhibited by both an IGF1-R
inhibitor and anti-AR neutralizing antibody, although EGFR inhibitor and anti-IGF1
neutralizing antibody were less effective. Altogether, these data suggested that in presence of
the two growth factors and their receptors, the anti-apoptotic effect is preferentially mediated
by AR and the IGF1-R pathway. The activation of IGF1-R by EGF-related peptides has never
been demonstrated although it was suggested in results from Swantek et al. in mouse embryos
fibroblastic cells. These authors showed that EGF induced a prolonged activation of ERK2
intracellular kinase in cell containing functional IGF1-R, but only a weaker and transitory
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activity of the kinase in cells that do not express IGF1-R or that express a mutated form of the
receptor. Transfection of cells with IGF1-R restored the capacity of EGF to induce prolonged
activation of ERK2 (36), thus suggesting that the IGF1-R was required to transduce the EGF-
mediated signal.
Whether AR can activate the IGF1-R by a direct or an indirect interaction is under
investigation. Interaction of AR with the IGF1-R could be direct or due to oligomerization of
AR and IGF1 before binding to the receptor. AR could also transactivate indirectly the
IGF1-R after binding on its specific receptor, the EGFR. Although transactivation of IGF1-R
by EGFR activation has never been described before, cases of transactivation of erbB family
receptors by IGF1-R have been observed (37-39). Moreover, in glioblastoma, IGF1-R
signaling is involved in resistance mechanisms to anti-EGFR therapy (34) and, in breast
cancer cell models that overexpress erbB-2/neu, an increased level of IGF1-R signaling
appears to interfere with the action of Trastuzumab, an anti-erbB2/neu antibody (35). By
using combinations of antisense oligonucleotides directed against erbB-2 mRNA and IGF1-R,
it has also been shown that IGF1-R directs erbB2 phosphorylation (62); this interaction
involves physical association of both receptors and the formation of an heteromeric complex.
Similar interaction between EGFR and IGF1-R has never been described.
Emergence of a tumoral clone resulted from accumulation of abnormalities resulting to a
prolonged survival and a stimulation of growth and mobility. We previously showed that
H358 NSCLC cells presented an increased resistance to p53 and BAX-mediated apoptosis
(63). Resistance to apoptosis in H358 cell line is linked to conformational abnormalities of the
BAX protein and an inhibition of its translocation from the cytosol to the mitochondria; this
phenomenon is reversed by treatment with caffeine. In this report, we characterized another
original mechanism of apoptosis inhibition in NSCLC cells. It remains to be determined if
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there is a link between both these observations and, in particular, if the activation of the
IGF1-R pathway by AR can modify the phosphorylation of the BCL2 family members and
inactivate BAX.
In conclusion, secretion of growth factors, in particular EGF-related peptides, by human
lung epithelial cells is well established, but the consequences of the coexpression of EGFR
and its ligands by malignant cells on lung tumor progression are still controversial as it is for
IGF1-R expression. Our study, which demonstrates for the first time the activation of IGF1-R
by AR, in addition to the stimulation of AR release by IGF1-R activation, is a very important
step in the elucidating the involvement of AR and IGF1 in lung tumor development and
progression. Further studies on the relevance of those growth factors in vivo on fresh tumor
samples will allow development of a new therapeutic strategy.
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FIGURE LEGENDS
Figure 1: Effect of serum withdrawal on apoptosis in H358 and H322 NSCLC cells.
Serum deprivation induces apoptosis in H322 but not in H358 NSCLC lines. A: Kinetics of
apoptosis induced by serum withdrawal in H322 (open circles) or H358 cells (filled circles).
Percentage of apoptosis was assessed by fluorescence microscopy after Hoechst staining of
the cells. Results are expressed as the mean ± SD of three independent experiments. B:
Agarose gel electrophoresis of DNA extracted from H322 or H358 cells cultured in RPMI-
serum 10 % (10) or in serum-free medium (0). DNA from H358 cells treated for 24 hours
with 100 nM staurosporine was used as positive control of apoptotic DNA fragmentation
(C+). C: Western blot analysis of the p32 pro-caspase-3 and p12 fragment of active caspase-3
in H322 or H358 cells cultured in RPMI-serum 10 % (10) or in serum-free medium (0).
D: Conditioned medium from H358 cells protects H322 cells from serum deprivation
apoptosis. Apoptosis in H322 cells was detected by two methods: detection of the p12 active
fragment of caspase-3 by immunoblotting or after counting Hoechst stained cells cultured in
RPMI-serum 10 % (10) or serum-free medium (0) or in serum-free conditioned medium from
H358 cells (CM).
Percentages of apoptosis are expressed as the mean ± SD of three independent experiments.
***: Statistically more than H358 CM; p<0.01.
Figure 2: Effect of tyrosine kinase receptors inhibition on serum deprivation apoptosis
in H322 cells.
H322 cells were cultured in RPMI medium supplemented with 10 % serum (10), serum-free
medium (0) or conditioned medium from H358 cells (CM). The activity of indicated
concentrations of AG825 (A), AG1295 (B), AG1024 (C), AG556 (D), and ZD1839 (E) was
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analyzed. Apoptosis was analyzed by fluorescence microscopy after Hoechst staining of cells
and by detection of the p12 active fragment of caspase-3 by immunoblotting. Percentage of
apoptosis detected in serum-free medium condition (0) was normalized at 100. Apoptosis was
expressed as a rate of apoptosis in serum-free medium and as the mean ± SD of three
independent experiments.
Figure 3: Effect of tyrosine kinase receptor inhibition on serum deprivation apoptosis in
H358 cells.
Western blotting analysis of pro-caspase-3 proteolytic activation in its p12 active fragment in
H358 cells cultured in serum-free medium in the presence of indicated concentrations in µM
of tyrphostins AG556, AG825, AG1024 or AG1295.
Figure 4: AR and IGF1 recombinant proteins inhibit serum deprived apoptosis in H322
cells.
H322 cells were cultured in medium supplemented with 10 % serum (10), in serum-free
medium (0), in conditioned medium from H358 cells (CM) or in serum-free medium
supplemented with the indicated concentrations of AR or IGF1 recombinant proteins.
Apoptosis was analyzed by immunolabelling of active caspase-3 and flow cytometry
detection. Percentage of apoptosis was expressed as a rate of apoptosis detected in serum-free
medium (0), normalized at 100. Data represent the mean ± SD of at least three independent
experiments. * p<0.05; ** p<0.005; statistically less than serum-free medium condition (0).
Figure 5: Role of IGF1-R and metalloproteases in AR and IGF1 secretions by serum-
deprived H358 cells.
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Kinetics of AR (left panel) or IGF1 (right panel) release were measure in H358 conditioned
medium using ELISA detection. 8x105 cells were incubated for the times indicated in serum-
free medium (0 % serum), in serum-free medium supplemented with AG1024 1 µM or 1,10-
phenanthroline 100 µM. Data were expressed as the mean ± SD of three independent
experiments.
Figure 6: Effect of H358 conditioned medium, AR and IGF1 on IGF1-R tyrosine
phosphorylation.
Serum-deprived H322 cells were incubated: A, for 30 minutes in serum-free medium (-), in
serum-free medium with IGF1 50 ng/ml (IGF1), or for indicated times in serum-free H358
CM (CM), B, for 30 minutes in serum-free medium (-), in H358 CM (CM), in H358 CM pre-
incubated with anti-AR neutralizing antibody (CM + Ac αAR), or in serum-free medium with
50 ng/ml of IGF1 (IGF1) or AR (AR), prior to detergent lysis and immunoprecipitation of the
IGF1-R β subunit. C, serum-deprived H358 cells were incubated for 30 minutes in serum-free
medium (-), in H358 CM (CM), or in serum-free medium with 50 ng/ml of IGF1 (IGF1) or
AR (AR), prior to detergent lysis and immunoprecipitation of the IGF1-R β subunit.
Tyrosine phosphorylation was visualized by protein immunoblotting with monoclonal anti-
phosphotyrosine IgG as described (upper lane). Equal loading of immunoprecipitated proteins
was confirmed by reprobing immunoblots with polyclonal anti-IGF1-R β subunit antibody
(lower lane). IgG: immunoglobulin control for immunoprecipitation. Data are representative
of at least three separate experiments.
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Table 1: Effect of tyrosine kinase receptors inhibition on serum deprivation apoptosis in
H358 cells.
The activity of tyrphostins AG556, AG1024, AG825 or AG1295 on apoptosis in H358 cells
cultured in medium supplemented (10 % serum) or not (0 % serum) with serum was analyzed.
Apoptosis was detected by fluorescence microscopy after Hoechst staining of cells.
Percentage of apoptosis was expressed as the mean ± SD of at least three independent
experiments.
Table 2: Effect of neutralization of the members of the EGF and IGF families on the
anti-apoptotic activity of H358 conditioned medium.
H358 conditioned medium (CM) was pre-incubated with neutralizing antibodies, before being
added to serum-deprived H322 cells for 96 h. Apoptosis was detected by fluorescence
microscopy after Hoechst staining of cells. Percentage of apoptosis was expressed as a rate of
serum deprivation apoptosis in H322 cells. Data represent the mean ± SD of at least three
independent experiments.
ND50: neutralizing dose 50 given by the manufacturor, Ig: immunoglobulin used as control,
BTC: betacellulin.
Table 3: Detection of AR and IGF1 in cell culture mediums.
AR and IGF1 concentrations were measure in H358, H322 or other cell lines conditioned
media using ELISA detection. Five millions of cells were incubated during 72 h in serum-free
medium. Data were expressed as the mean ± SD of at least three independent experiments.
NSCLC: non small cell lung cells, SCLC: small cell lung cells, LCNEC: large cell
neuroendocrine lung cells.
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Table 1
Receptor Inhibitor Concentration
(µM)
Apoptosis
10 % serum
Apoptosis
0 % serum
Control 0.9 ± 0,1 1.9 ±   1,3
EGFR AG 556 2 4.1 ±   0,0
10 2.2 ± 1.3 46.5 ± 14.0
IGF1-R AG 1024 5 11.2 ±   3.3
10 1.7 ± 1.2 29.3 ±   0.2
Erb-B2/Neu AG 825 10 4.0 ±   0.0
20 2.3 ± 1.2 4.4 ±   0.6
PDGFR AG 1295 40 0.9 ± 0.8 4.7 ±   1.2
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Table 2
ND50
(µg/ml)
Used
concentrations
(µg/ml)
Apoptosis
(% / Control)
0 100
CM 7.1 ±   8.8
CM + Ig 3.4 ±   6.6
CM +
anti-EGF Ab 0.04-0.08 up to 5 4.4 ±   6.2
anti-TGFα Ab 0.2-0.4 up to 5 11.3 ± 10.8
anti-AR Ab 5-15 10 45.9 ±   8.6
15 104.2 ± 16.7
CRM197 10 10 16.9 ± 15.0
(HB-EGF) 20 22.1 ± 19.7
anti-BTC Ab 0.04-0.08 up to 5 17.3 ± 14.5
anti-IGF1 Ab 2-5 5 47.7 ± 10.0
10 55.1 ± 19.3
anti-IGFII Ab 5-15 up to 30 12.2 ± 10.6
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Table 3
Cell lines AR
pg/ml
IGF1
pg/ml
H358 NSCLC 5603 ± 1635   920 ± 113
H322 NSCLC Not detectable   345 ± 361
CALU-1 NSCLC 100 ±   11 810 ±   14
A549 NSCLC 118 ±   17 810 ± 127
H2170 NSCLC 129 ±   13 487 ± 217
H69 SCLC 105 ±   18 690
H1417 SCLC 133 ±     7   70 ±   14
H810 LCNEC 152 ±   10   49 ±     2
H2106 LCNEC
H720 Human lung atypical carcinoid 195 ±   60 150
NHBE Normal human bronchial
epithelial cells
813 ±   46 60
SAOS Human osteosarcoma 145 ±   25 245 ±   78
MCF7 Human breast adenocarcinoma   85 ±   12 775 ±   78
HELA Human cervix adenocarcinoma 178 ±     8 745 ± 149
HEL Human erythroleukemia 100 ±   12 440 ± 170
K562 Human chronic myelogenous
leukemia
  82 ±   20 365 ±   21
JURKAT Human T cell leukemia 124 ±   18 215 ±   92
CHO Chinese hamster ovary 175 ± 118 805 ±   35






